Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 713Pancreatic Neoplasms 500Carcinoma, Hepatocellular 333Colonic Neoplasms 282Stomach Neoplasms 277Rectal Neoplasms 236Esophageal Neoplasms 198Neoplasms 194Liver Neoplasms 169Neoplasm Metastasis 164Carcinoma, Non-Small-Cell Lung 125Breast Neoplasms 111Cholangiocarcinoma 91Ovarian Neoplasms 87Lung Neoplasms 85Gastrointestinal Neoplasms 80Melanoma 76Gastrointestinal Stromal Tumors 68Adenocarcinoma Of Esophagus 64Adenocarcinoma 62Prostatic Neoplasms 59Biliary Tract Neoplasms 58Carcinoma, Renal Cell 56Sarcoma 54Head and Neck Neoplasms 54Urinary Bladder Neoplasms 51Gallbladder Neoplasms 49Barrett Esophagus 49Bile Duct Neoplasms 47Anus Neoplasms 47

Interventions

trifluridine tipiracil drug combination 1tipiracil 1pembrolizumab 1cabozantinib 1andecaliximab 1Trifluridine 1S 1 (combination) 1Oxaliplatin 1Nivolumab 1Irinotecan 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Gastric Adenocarcinoma × Gastrointestinal × Clear all
NCT04164979 2025-08-11

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 2 Active not recruiting
34 enrolled 11 charts
Gastrointestinal

Gastric Adenocarcinoma

NCT04162665 2025-01-09

Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

Washington University School of Medicine

Phase 2 Terminated
4 enrolled 11 charts
Gastrointestinal

Gastric Adenocarcinoma

NCT04074343 2024-02-02

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 1 Completed
20 enrolled 9 charts
Gastrointestinal

Gastric Adenocarcinoma

NCT02862535 2020-12-24

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Gilead Sciences

Phase 1 Terminated
36 enrolled 17 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡